In addition, the anti-AML activity and safety of several other multikinase inhibitors with FLT3 inhibitory activity, such as AT-9283, ENMD-981693, 4SC-203, cabozantinib, and CR-4, are also being evaluated in the clinic (NCT01054937, NCT01961765).116. This evidence concerns the gene FLT3 and acute myeloid leukemia.